PARAMYLOIDOSIS (or primary amyloidosis)1 is a rare condition, only about 70 cases having been reported in the literature. Paramyloid deposition is widespread in the body, and as a result its clinic ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Amyloidosis is a rare protein-related condition that occurs when your body produces too many amyloid proteins, causing damage ...

Hemorrhages may cause dementia directly by triggering the accumulation of a protein called amyloid beta in the brain and its blood vessels, which can disrupt brain function. Or hemorrhage and ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

“This follow-up study of gantenerumab, an anti-amyloid drug that previously failed to slow cognitive decline in people at risk of Alzheimer’s disease, suggests that extended use of anti-amyloid ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...